Weihong Xu

Weihong Xu

Auto-generated profile, based on publicly available information

Weihong Xu

Stanford Genome Technology Center, Palo Alto, California, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJunhee Seok
Junhee Seok
HWH. Shaw Warren
H. Shaw Warren
ACAlex G. Cuenca
Alex G. Cuenca
MMMichael N. Mindrinos
Michael N. Mindrinos
HBHenry V. Baker
Henry V. Baker
WWWing H Wong
Wing H Wong
A cornerstone of modern biomedical research is the use of mouse models to explore basic pathophysiological mechanisms, evaluate new therapeutic approaches, and make go or no-go decisions to carry new drug candidates forward into clinical trials. Systematic studies evaluating how well murine models mimic human inflammatory diseases are nonexistent. Here, we show that, although acute inflammatory stresses from different etiologies result in highly similar genomic responses in humans, the responses in corresponding mouse models correlate poorly with the human conditions and also, one another. Among genes changed significantly in humans, the murine orthologs are close to random in matching their human counterparts (e.g., R 2 between 0.0 and 0.1). In addition to improvements in the current animal model systems, our study supports higher priority for translational medical research to focus on the more complex human conditions rather than relying on mouse models to study human inflammatory diseases.

21 November 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WXWenzhong Xiao
Wenzhong Xiao
MMMichael N. Mindrinos
Michael N. Mindrinos
JSJunhee Seok
Junhee Seok
JCJoseph Cuschieri
Joseph Cuschieri
ACAlex G. Cuenca
Alex G. Cuenca
RTRonald G. Tompkins
Ronald G. Tompkins
Human survival from injury requires an appropriate inflammatory and immune response. We describe the circulating leukocyte transcriptome after severe trauma and burn injury, as well as in healthy subjects receiving low-dose bacterial endotoxin, and show that these severe stresses produce a global reprioritization affecting >80% of the cellular functions and pathways, a truly unexpected “genomic storm.” In severe blunt trauma, the early leukocyte genomic response is consistent with simultaneously increased expression of genes involved in the systemic inflammatory, innate immune, and compensatory antiinflammatory responses, as well as in the suppression of genes involved in adaptive immunity. Furthermore, complications like nosocomial infections and organ failure are not associated with any genomic evidence of a second hit and differ only in the magnitude and duration of this genomic reprioritization. The similarities in gene expression patterns between different injuries reveal an apparently fundamental human response to severe inflammatory stress, with genomic signatures that are surprisingly far more common than different. Based on these transcriptional data, we propose a new paradigm for the human immunological response to severe injury.

1 August 2009 in Cell
Verified
Journal Article
Closed access
DHDan Han
Dan Han
ALAlana G. Lerner
Alana G. Lerner
LWLieselotte Vande Walle
Lieselotte Vande Walle
JUJohn-Paul Upton
John-Paul Upton
WXWeihong Xu
Weihong Xu
FPFeroz R. Papa
Feroz R. Papa

10 August 2014 in Nature
Verified
Journal Article
Open access
PDF file
PHPei Han
Pei Han
WLWei Li
Wei Li
CLChiou-Hong Lin
Chiou-Hong Lin
JYJin Yang
Jin Yang
CSChing Shang
Ching Shang
CCChing-Pin Chang
Ching-Pin Chang
Here, a long noncoding RNA, termed Mhrt, is identified in the loci of myosin heavy chain (Myh) genes in mice and shown to be capable of suppressing cardiomyopathy in the animals, as well as being repressed in diseased human hearts. Ching-Pin Chang and colleagues identify a cardioprotective long noncoding RNA (lncRNA) in the loci of the myosin heavy chain genes Myh6 and Myh7. The lncRNA, termed Mhrt, is capable of suppressing cardiomyopathy, probably by binding the helicase domain of the chromatin remodelling factor Brg1 and preventing it from recognizing its genomic targets. In turn, Mhrt is negatively regulated by the Brg1–Hdac–Parp1 complex during pathological stress and is repressed in diseased human hearts. Restoring Mhrt expression in the stressed heart protects the heart from hypertrophy and failure. The role of long noncoding RNA (lncRNA) in adult hearts is unknown; also unclear is how lncRNA modulates nucleosome remodelling. An estimated 70% of mouse genes undergo antisense transcription1, including myosin heavy chain 7 (Myh7), which encodes molecular motor proteins for heart contraction2. Here we identify a cluster of lncRNA transcripts from Myh7 loci and demonstrate a new lncRNA–chromatin mechanism for heart failure. In mice, these transcripts, which we named myosin heavy-chain-associated RNA transcripts (Myheart, or Mhrt), are cardiac-specific and abundant in adult hearts. Pathological stress activates the Brg1–Hdac–Parp chromatin repressor complex3 to inhibit Mhrt transcription in the heart. Such stress-induced Mhrt repression is essential for cardiomyopathy to develop: restoring Mhrt to the pre-stress level protects the heart from hypertrophy and failure. Mhrt antagonizes the function of Brg1, a chromatin-remodelling factor that is activated by stress to trigger aberrant gene expression and cardiac myopathy3. Mhrt prevents Brg1 from recognizing its genomic DNA targets, thus inhibiting chromatin targeting and gene regulation by Brg1. It does so by binding to the helicase domain of Brg1, a domain that is crucial for tethering Brg1 to chromatinized DNA targets. Brg1 helicase has dual nucleic-acid-binding specificities: it is capable of binding lncRNA (Mhrt) and chromatinized—but not naked—DNA. This dual-binding feature of helicase enables a competitive inhibition mechanism by which Mhrt sequesters Brg1 from its genomic DNA targets to prevent chromatin remodelling. A Mhrt–Brg1 feedback circuit is thus crucial for heart function. Human MHRT also originates from MYH7 loci and is repressed in various types of myopathic hearts, suggesting a conserved lncRNA mechanism in human cardiomyopathy. Our studies identify a cardioprotective lncRNA, define a new targeting mechanism for ATP-dependent chromatin-remodelling factors, and establish a new paradigm for lncRNA–chromatin interaction.

27 November 2015 in Science
Verified
Journal Article
Closed access
PDF file
LYLuhan Yang
Luhan Yang
MGMarc Güell
Marc Güell
DNDong Niu
Dong Niu
HGHaydy George
Haydy George
ELEmal Lesha
Emal Lesha
GCGeorge Church
George Church
Virally cleansing the pig genome: Transplants from pigs could be a solution to a shortage of human organs for transplantation. Unfortunately, porcine endogenous retroviruses (PERVs) are rife in pigs and can be transmitted to humans, risking disease. L. Yang et al. integrated CRISPR-Cas into the pig cell genome, where continuous induction of the Cas9 editing enzyme resulted in the mutation of every single PERV reverse transcriptase gene. This prevented replication of all copies of PERV, viral infection, and transmission to human cells. Science , this issue p. 1101

25 June 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
WZWenqian Zhang
Wenqian Zhang
YYYing Yu
Ying Yu
FHFalk Hertwig
Falk Hertwig
JTJean Thierry-Mieg
Jean Thierry-Mieg
WZWenwei Zhang
Wenwei Zhang
MFMatthias Fischer
Matthias Fischer
Background: Gene expression profiling is being widely applied in cancer research to identify biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for transcriptome-based applications beyond the limitations of microarrays, we sought to systematically evaluate the performance of RNA-seq-based and microarray-based classifiers in this MAQC-III/SEQC study for clinical endpoint prediction using neuroblastoma as a model. Results: We generate gene expression profiles from 498 primary neuroblastomas using both RNA-seq and 44 k microarrays. Characterization of the neuroblastoma transcriptome by RNA-seq reveals that more than 48,000 genes and 200,000 transcripts are being expressed in this malignancy. We also find that RNA-seq provides much more detailed information on specific transcript expression patterns in clinico-genetic neuroblastoma subgroups than microarrays. To systematically compare the power of RNA-seq and microarray-based models in predicting clinical endpoints, we divide the cohort randomly into training and validation sets and develop 360 predictive models on six clinical endpoints of varying predictability. Evaluation of factors potentially affecting model performances reveals that prediction accuracies are most strongly influenced by the nature of the clinical endpoint, whereas technological platforms (RNA-seq vs. microarrays), RNA-seq data analysis pipelines, and feature levels (gene vs. transcript vs. exon-junction level) do not significantly affect performances of the models. Conclusions: We demonstrate that RNA-seq outperforms microarrays in determining the transcriptomic characteristics of cancer, while RNA-seq and microarray-based models perform similarly in clinical endpoint prediction. Our findings may be valuable to guide future studies on the development of gene expression-based predictive models and their implementation in clinical practice.